Case Report: Semaglutide-associated depression: a report of two cases.

Li JR, Cao J, Wei J, Geng W

Frontiers in psychiatry29 Aug 2023Cited by 34 (Europe PMC)

PMID37706035PMCIDPMC10495976DOI10.3389/fpsyt.2023.1238353PepBankPUB-37706035

Summary

Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the U.S. Food and Drug Administration (FDA). No psychiatric adverse effect associated with semaglutide has been reported so far. Here we report two cases of semaglutide-associated depression. One is a middle-aged man with no previous history of depression who developed depressive symptoms about 1 month after taking semaglutide. The other one is a middle-aged woman with recurrent depressive disorder whose symptoms also recurred about 1 month after semaglutide treatment. Depression was improved or relieved after discontinuation of semaglutide in both cases. Possible psychiatric adverse effects of depression should be taken into consideration when semaglutide is administered to patients.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanCase report or seriesSafety outcome
In both cases, depression improved or was relieved after semaglutide was stopped.
In plain wordsIn both people, depression got better or went away after semaglutide was stopped.
Peptide
Semaglutide
Outcome
DecreaseDepression after discontinuation of semaglutide
Study
n = 2
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
Depression was improved or relieved after discontinuation of semaglutide in both cases.
1 context sentence(design, population, supporting numbers)
Summary · context
Here we report two cases of semaglutide-associated depression.
Show in the study text Report a problemFND-3770603503
02HumanCase report or seriesSafety outcome
In a middle-aged man with no previous depression, depressive symptoms appeared about 1 month after starting semaglutide.
In plain wordsIn one man with no history of depression, depression symptoms began about a month after starting semaglutide.
Peptide
Semaglutide
Outcome
IncreaseDepressive symptoms in a man without prior depression
Study
n = 1
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
One is a middle-aged man with no previous history of depression who developed depressive symptoms about 1 month after taking semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Here we report two cases of semaglutide-associated depression.
Show in the study text Report a problemFND-3770603501
03HumanCase report or seriesSafety outcome
In a middle-aged woman with recurrent depressive disorder, symptoms recurred about 1 month after semaglutide treatment.
In plain wordsIn one woman with recurrent depression, symptoms came back about a month after starting semaglutide.
Peptide
Semaglutide
Outcome
IncreaseRecurrence of depression in a woman with recurrent depressive disorder
Study
n = 1
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
The other one is a middle-aged woman with recurrent depressive disorder whose symptoms also recurred about 1 month after semaglutide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Here we report two cases of semaglutide-associated depression.
Show in the study text Report a problemFND-3770603502

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.